undamentalytics Newsletter
Sign in

ADC Therapeutics SA (ADCT) stock

Add to watchlist

Add holding +

NYSE: ADCT NYSE Biotechnology Next results ~November 10, 2026

C Fundamentals grade

ADC Therapeutics SA is a US-listed company in the biotechnology industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$2.0

Valuation models combined (2)

Base case. Range ~$1.9–$2.4. Weighted average of 2 models (growth cash-flow model, forward price-to-sales vs peers), the growth cash-flow model counting double.

Price vs value

No Buy/Hold/Sell rating is issued: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

ADC Therapeutics SA valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 1 selling0 purchases and 6 sales by directors and officers, last 12 monthsInsider trades
  • Funds69 adding, 60 cuttingOf 30 active managers that changed their stake, 17 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter ADC Therapeutics SA files

Where ADC Therapeutics SA stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $80m, up 3.0% on a year earlier, slower than the 4.4% growth a quarter earlier. Free-cash-flow margin rose to -128.5% from -165.6% a year earlier. Operating margin widened to -125.1% from -182.0%. The diluted share count is up 38.3% on a year earlier, which dilutes existing holders. It passes 1 of our 3 financial-health checks. Our valuation models combined value is $2.36 a share, against a share price of $1.53.

Source: 10-Q filed August 13, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 10, 2026 (estimated)

ADC Therapeutics SA's trailing-twelve-month revenue grew 3.0% year on year, with a free-cash-flow margin of -128.5%. Where it lags: change in share count of 38.3% ranks 138 of 156 biotechnology companies we cover.

Current signal Free cash flow diverging from earnings: TTM free cash flow grew 20.0% while net income grew 43.0%: a 23pp divergence.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Margins widening. Operating margin is up 56.9 points on a year ago.
  • Net cash. Cash exceeds long-term debt by $0.2bn.

Things to watch

  • Loss-making. Operating margin is -125.1%: costs exceed revenue.
  • Burning cash. Free cash flow was -128.5% of revenue over the last 12 months.
  • Share dilution. Diluted shares rose 38.3% in a year.
  • Volatile shares. Over the past year the shares showed annualised volatility of 98% and a beta of 1.3 against the S&P 500.
  • Insiders selling. 1 insiders sold $20M of stock over the past 365 days and none bought (0% under pre-set trading plans).
  • Short interest rising. Shares sold short rose 18% in a month to 5.9% of tradable shares.

Latest results: FY2026 Q2

Filed August 13, 2026
Earnings per share
-$0.11 against an average estimate of -$0.22: beat by 49.1%
Revenue
$19m, up 2.2% on a year earlier
Share reaction
-22.0% in the first session after the results on October 13, 2026, against -1.1% for the S&P 500
Next report
November 10, 2026

ADC Therapeutics SA's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+0.7%
  • 1 week+2.0%
  • 1 month+36.3%
  • This year-56.4%
  • 1 year-65.5%
  • 5 years-94.9%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$79.6M
Operating margin
-125.1%
Net margin
-121.8%
EPS (TTM, diluted)
$-0.65

Growth

Revenue growth
+3.0%
Change in growth rate
−1.4 pts
Share count change
+38.3%

Cash

Free cash flow (TTM)
-$102M
FCF margin
-128.5%
Stock pay % of revenue
12.2%

Earnings

Last results
October 13, 2026

News & updates

Updated November 2, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Announcement
  2. Results
  3. Results
  4. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

ADC Therapeutics SA valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Valuation models

We value ADC Therapeutics SA as an operating company, with every model that fits that kind of business. Cost of equity 11.5%: the 10-year Treasury yield (4.9%) plus a beta of 1.45 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$1.9 ~$1.0–$2.6 Primary model, counts double
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no positive earnings in the latest twelve months
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: book value or earnings not available
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$2.4 ~$2.5–$9.4 Included, half weight
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: revenue and margins don't support a positive value
Combined value Weighted average of the models that apply: the primary model (growth cash-flow model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$2.0 ~$1.9–$2.4 2 models

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare ADC Therapeutics SA with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 2022202320242025Now
Share price$3.84$1.66$1.99$3.53$1.54
Market value$300m$136m$193m$449m$230m
+ Net debt (− = net cash)−$217m−$166m−$137m−$146m−$102m
Enterprise value$83m−$30m$56m$303m$127m
Multiples
Price / sales 1.4x2.0x2.7x5.5x2.9x
Price / earnings —————
Price / free cash flow —————
EV / EBITDA —————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 10, 2026, before the open. Analysts expect revenue of $19m for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$0.75 +33% $81m −1%
Next −$0.68 +10% $101m +25%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −12.1% on 90 days ago. In the last 30 days, 4 analysts raised ADC Therapeutics SA's forecast and 0 cut it.

Consensus EPS forecast ADC Therapeutics SA, last 90 days
−$1.00 −$0.50 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$0.86 Current fiscal year, 60 days ago: −$0.86 Current fiscal year, 30 days ago: −$0.76 Current fiscal year, 7 days ago: −$0.76 Current fiscal year, Now: −$0.75 −$0.75 Next fiscal year, 90 days ago: −$0.66 Next fiscal year, 60 days ago: −$0.66 Next fiscal year, 30 days ago: −$0.68 Next fiscal year, 7 days ago: −$0.68 Next fiscal year, Now: −$0.68 −$0.68

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$0.86−$0.66
60 days ago −$0.86−$0.66
30 days ago −$0.76−$0.68
7 days ago −$0.76−$0.68
Now −$0.75−$0.68

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.22 −$0.11 +49.1%
Mar 2026 −$0.20 −$0.21 −4.1%
Dec 2025 −$0.27 −$0.04 +85.1%
Sept 2025 −$0.36 −$0.30 +17.4%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

5 analysts, Oct 2026
Buy360%
Hold240%
Sell00%

Monthly trend

  1. Oct 2026325
  2. Sep 2026325
  3. Aug 2026325

Counts of recommendations published by analysts covering ADC Therapeutics SA, by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
5.9%
of tradable shares
Days to cover
3.44
at average volume
Short interest, 1 month
+18%
to October 15, 2026
Held by institutions
68%
of shares
Held by insiders
14.4%
of shares
Employees
188
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months −65.5%

$4.46 on October 31, 2025 to $1.54

ThenNowEffect
Revenue (last 12 months) $77m $80m +3.0%
P/S multiple 6.2x 2.9x −53.7%
Share count 108m 149m −27.7%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
ADCT−37%−81%−57%+20%+77%−56%
Industry peers (median)−35%−56%−17%−29%−5%−26%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
ADCT33%25%33%33%58%64%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
ADCT−43%−86%−91%−64%−46%−80%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since May 18, 2020: 99% from July 2, 2020 to November 9, 2023. Getting back needed a 10808% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$0.96 – $4.88
From 52-week high
−68.4%
vs 50-day average
+16.9%
vs 200-day average
−37.7%
Volatility (1 year)
98%
Beta vs S&P 500
1.27

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
4 up, 8 down
typical move ±11.1%
After a week
2 up, 10 down
typical move ±14.8%
After a month
4 up, 7 down
typical move ±26.1%
Results releasedNext dayS&P 500 next day5 days21 days
October 13, 2026 −22.0% −1.1% −18.3% —
August 13, 2026 −17.9% +0.5% −22.0% −9.8%
May 4, 2026 −1.8% +0.4% −9.1% −19.6%
March 10, 2026 +15.4% −0.3% −2.8% −11.1%
January 8, 2026 +0.3% +0.7% −2.7% +9.3%
November 10, 2025 −1.7% +1.8% −1.7% −0.7%
October 14, 2025 −7.6% +0.3% −10.4% −12.1%
August 12, 2025 +15.3% +1.4% +16.0% +24.3%
May 14, 2025 +28.0% +0.6% +49.2% +171.2%
March 27, 2025 −5.7% −2.3% −22.2% −7.6%
January 13, 2025 −9.0% +0.3% −6.4% −21.3%
November 7, 2024 −8.4% +1.2% −17.2% +0.3%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

ADC Therapeutics SA in five measures

Fundamentals grade C
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) ADC Therapeutics SA
$65M $70M $75M $80M $85M FY23 Q4 FY24 Q2 FY24 Q4 FY25 Q2 FY25 Q4 FY26 Q2 Revenue (TTM), FY23 Q4: $69.6M Revenue (TTM), FY24 Q1: $68.6M Revenue (TTM), FY24 Q2: $66.7M Revenue (TTM), FY24 Q3: $70.7M Revenue (TTM), FY24 Q4: $70.8M Revenue (TTM), FY25 Q1: $75.8M Revenue (TTM), FY25 Q2: $77.2M Revenue (TTM), FY25 Q3: $75.2M Revenue (TTM), FY25 Q4: $81.4M Revenue (TTM), FY26 Q1: $79.2M Revenue (TTM), FY26 Q2: $79.6M $79.6M

Source: SEC EDGAR filings. Retrieved October 31, 2026.

View chart data
Period Revenue (TTM)
FY23 Q4 $69.6M
FY24 Q1 $68.6M
FY24 Q2 $66.7M
FY24 Q3 $70.7M
FY24 Q4 $70.8M
FY25 Q1 $75.8M
FY25 Q2 $77.2M
FY25 Q3 $75.2M
FY25 Q4 $81.4M
FY26 Q1 $79.2M
FY26 Q2 $79.6M
Revenue growth, TTM YoY ADC Therapeutics SA
0% 5% 10% 15% 20% FY24 Q4 FY25 Q2 FY25 Q4 FY26 Q2 Revenue growth, TTM YoY, FY24 Q4: 1.8% Revenue growth, TTM YoY, FY25 Q1: 10.5% Revenue growth, TTM YoY, FY25 Q2: 15.7% Revenue growth, TTM YoY, FY25 Q3: 6.4% Revenue growth, TTM YoY, FY25 Q4: 14.9% Revenue growth, TTM YoY, FY26 Q1: 4.4% Revenue growth, TTM YoY, FY26 Q2: 3.0% 3.0%

Source: SEC EDGAR filings. Retrieved October 31, 2026.

View chart data
Period Revenue growth, TTM YoY
FY24 Q4 1.8%
FY25 Q1 10.5%
FY25 Q2 15.7%
FY25 Q3 6.4%
FY25 Q4 14.9%
FY26 Q1 4.4%
FY26 Q2 3.0%
Operating margin (TTM) ADC Therapeutics SA
-300% -200% -100% 0% FY23 Q4 FY24 Q2 FY24 Q4 FY25 Q2 FY25 Q4 FY26 Q2 Operating margin (TTM), FY23 Q4: -238.6% Operating margin (TTM), FY24 Q1: -217.7% Operating margin (TTM), FY24 Q2: -207.9% Operating margin (TTM), FY24 Q3: -195.4% Operating margin (TTM), FY24 Q4: -184.4% Operating margin (TTM), FY25 Q1: -165.5% Operating margin (TTM), FY25 Q2: -182.0% Operating margin (TTM), FY25 Q3: -180.9% Operating margin (TTM), FY25 Q4: -149.3% Operating margin (TTM), FY26 Q1: -149.4% Operating margin (TTM), FY26 Q2: -125.1% -125.1%

Source: SEC EDGAR filings. Retrieved October 31, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q4 -238.6%
FY24 Q1 -217.7%
FY24 Q2 -207.9%
FY24 Q3 -195.4%
FY24 Q4 -184.4%
FY25 Q1 -165.5%
FY25 Q2 -182.0%
FY25 Q3 -180.9%
FY25 Q4 -149.3%
FY26 Q1 -149.4%
FY26 Q2 -125.1%
FCF margin (TTM) ADC Therapeutics SA
-300% -200% -100% 0% FY23 Q4 FY24 Q2 FY24 Q4 FY25 Q2 FY25 Q4 FY26 Q2 FCF margin (TTM), FY23 Q4: -175.3% FCF margin (TTM), FY24 Q1: -218.8% FCF margin (TTM), FY24 Q2: -219.9% FCF margin (TTM), FY24 Q3: -190.5% FCF margin (TTM), FY24 Q4: -176.0% FCF margin (TTM), FY25 Q1: -180.3% FCF margin (TTM), FY25 Q2: -165.6% FCF margin (TTM), FY25 Q3: -175.9% FCF margin (TTM), FY25 Q4: -173.8% FCF margin (TTM), FY26 Q1: -144.7% FCF margin (TTM), FY26 Q2: -128.5% -128.5%

Source: SEC EDGAR filings. Retrieved October 31, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q4 -175.3%
FY24 Q1 -218.8%
FY24 Q2 -219.9%
FY24 Q3 -190.5%
FY24 Q4 -176.0%
FY25 Q1 -180.3%
FY25 Q2 -165.6%
FY25 Q3 -175.9%
FY25 Q4 -173.8%
FY26 Q1 -144.7%
FY26 Q2 -128.5%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q, 20-F. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 210 70 71 81 80
Gross profit 207 67 65 76 —
EBITDA −122 −165 −129 −121 —
Operating income −123 −166 −131 −121 −100
Net income −157 −240 −158 −143 −97
Diluted EPS −$2.01 −$2.94 −$1.62 −$1.12 −$0.65
Growth (year on year)
Revenue — −66.9% +1.8% +14.9% +3.0%
Margins
Gross margin 98.4% 96.4% 91.6% 92.9% —
EBITDA margin −58.3% −236.9% −182.6% −148.5% —
Operating margin −58.8% −238.6% −184.4% −149.3% −125.1%
Net margin −74.9% −345.1% −222.8% −175.3% −121.8%
Free-cash-flow margin −66.2% −175.3% −176.0% −173.8% −128.5%
Cash flow
Cash from operations −138 −119 −124 −141 −102
Capital spending 1 3 1 0 0
Free cash flow −139 −122 −125 −141 −102
Stock-based pay 49 13 7 7 10
Free cash flow after stock pay −188 −135 −131 −148 −112
Balance sheet
Cash 326 279 251 261 219
Total debt 110 113 114 116 117
Net debt (negative = net cash) −217 −166 −137 −146 −102
Diluted shares 78m 82m 97m 127m 149m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

1 of 3 checks passed · June 30, 2026
What it owns · $279m
Short-term assets $262mLonger-term assets $18m
What it owes, and who funded it · $508m
Short-term liabilities $86mLonger-term liabilities $421mShareholders' equity $-228m
  • Short-term assets cover short-term liabilities $262m of assets due within a year against $86m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $262m short-term assets against $421m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Operating income of −$100m against $52m of interest.

From ADC Therapeutics SA's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+38.3%
year over year
R&D spending
103.3%
of revenue

Competitors: side by side with peers

Closest by revenue in biotechnology
Last 12 months unless stated ADCT AAPG PLX BCYC ASMB CGEN Median
Revenue, last 12 months $80m $80m $81m $84m $75m $73m $56m
Revenue growth, last 12 months 3.0% −41.4% 30.1% 194.7% 125.1% 161.1% 12.6%
Revenue growth, 3-year average — — 6.1% 49.8% −3.3% 302.6% 13.7%
Revenue growth, latest quarter 2.2% — 27.1% 190.2% 38.9% — 10.2%
Gross margin — 91.5% 69.2% — — 87.3% 82.9%
Operating margin −125.1% — 28.9% −189.4% −11.8% 43.1% −189.4%
Operating margin, 3-year average −171.7% — 1.1% −581.7% −126.0% −255.7% −363.5%
Net margin −121.8% −216.5% 23.5% −169.8% −0.1% 48.6% −169.8%
Cash from operations / revenue −128.5% −204.5% 12.3% −209.7% −51.4% 43.5% −168.0%
Free-cash-flow margin −128.5% −209.3% 9.5% −211.9% −51.5% 43.1% −162.4%
Free-cash-flow margin, 3-year average −171.3% — −2.3% −539.0% −35.8% −216.6% −310.0%
Stock pay / revenue 12.2% 3.6% 2.4% 36.4% 8.9% 2.6% 20.0%
Change in share count 38.3% 17.9% −4.1% 0.6% 50.8% 4.8% 8.2%

Median of all 184 companies we cover in biotechnology. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

184 biotechnology companies
Measure Company Peer median Rank
Revenue growth Growth 3.0% 12.6% 105 of 172
Change in growth rate Growth -1.4pp -0.1pp 92 of 172
Operating margin Profitability -125.1% -189.4% 79 of 175
Net margin Profitability -121.8% -157.3% 83 of 180
Free-cash-flow margin Cash generation -128.5% -145.4% 86 of 176
Stock pay as % of revenue Cash generation 12.2% 19.2% 70 of 179
Change in share count Balance sheet 38.3% 7.9% 138 of 156

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Products $73.6M 90.4% ▲ 6.2%
License and Royalty Revenue $7.8M 9.6% ▲ 401.3%
License Revenues $5M 64.1% —
Royalty Revenue $2.8M 35.9% ▲ 80.2%
Geography
Region Revenue Share YoY
United States $73.6M 90.4% ▲ 6.2%
EMEA $7.8M 9.6% ▲ 401.3%

From ADC Therapeutics SA's 10-K filed March 10, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$99.9M
Institutions reporting
114
Shares held vs prior quarter
▲ 11.4%
Positions opened / closed
27 / 30

Top buyers and sellers, Q2 2026: 69 institutions bought and 60 sold ; the biggest buyer was Nantahala Capital Management, LLC (+19.1M shares) and the biggest seller Eventide Asset Management, LLC (−5.7M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Nantahala Capital Management, LLC $26.4M 24.7M 26.4% ▲ 340.4%
Redmile Group, LLC $12.3M 11.5M 12.3% ▼ 25.5%
Tcg Crossover Management, LLC $12.2M 11.4M 12.2% 0.0%
Prosight Management, LP $8.4M 7.8M 8.4% ▼ 5.7%
Blackrock, Inc. $7.5M 7.0M 7.5% ▲ 12.3%
Point72 Asset Management, L.P. $3.9M 3.6M 3.9% ▲ 7.9%
Morgan Stanley $3.3M 3.1M 3.3% ▼ 20.0%
Millennium Management LLC $3.1M 2.9M 3.1% ▼ 7.0%
Citadel Advisors LLC $2.2M 2.1M 2.2% ▲ 413.7%
Goldman Sachs Group Inc $2M 1.9M 2.0% ▲ 15.8%
State Street Corp $1.8M 1.7M 1.8% ▲ 7.6%
Geode Capital Management, LLC $1.5M 1.4M 1.5% ▲ 20.1%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not ADC Therapeutics SA's complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $19.6M 6 trades by 1 insider · 0% under pre-set plans
Net ▼ $19.6M net selling
Insider Date Trade Shares Price Value
Redco Ii Master Fund, L.P. 10% owner April 2, 2026 Sell 2,529,491 $3.28 $8.3M
Redco Ii Master Fund, L.P. 10% owner April 2, 2026 Sell 2,634,506 $3.28 $8.6M
Redco Ii Master Fund, L.P. 10% owner April 1, 2026 Sell 169,265 $3.80 $643,207
Redco Ii Master Fund, L.P. 10% owner April 1, 2026 Sell 162,517 $3.80 $617,565
Redco Ii Master Fund, L.P. 10% owner March 31, 2026 Sell 188,407 $3.75 $706,526
Redco Ii Master Fund, L.P. 10% owner March 31, 2026 Sell 196,229 $3.75 $735,859

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

  • October 13, 2026
  • August 13, 2026
  • May 4, 2026
  • March 10, 2026
  • January 8, 2026
  • November 10, 2025

Recent SEC filings

Data status

When each part of this page on ADC Therapeutics SA was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

ADC Therapeutics SA in brief

What does ADC Therapeutics SA do?
ADC Therapeutics SA is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is ADC Therapeutics SA's stock ticker?
ADC Therapeutics SA trades under the ticker ADCT on NYSE. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is ADC Therapeutics SA's revenue, and how fast is it growing?
Over its most recent trailing twelve months, ADC Therapeutics SA reported revenue of $79.6M, 3.0% higher than a year earlier, according to its SEC filings.
What is ADC Therapeutics SA's free cash flow?
ADC Therapeutics SA's free-cash-flow margin is -128.5% of revenue over the trailing twelve months, ranking 86 of the 176 biotechnology companies we cover.
Who are ADC Therapeutics SA's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Nantahala Capital Management, LLC, Redmile Group, LLC and Tcg Crossover Management, LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is ADC Therapeutics SA's market cap?
On November 2, 2026, ADC Therapeutics SA's market capitalisation was about $230M and net debt of -$102M. Market figures come from third-party market data and may be delayed.
Who are ADC Therapeutics SA's competitors?
In our Biotechnology peer group, the companies closest to ADC Therapeutics SA are Ascentage Pharma Group International, Protalix Biotherapeutics, Inc., Bicycle Therapeutics PLC, Assembly Biosciences, Inc. and Compugen LTD. The side-by-side comparison below sets their revenue, margins and growth against ADC Therapeutics SA's.
Are insiders buying or selling ADC Therapeutics SA stock?
Over the last 12 months, ADC Therapeutics SA's directors and officers reported 0 open-market purchases and 6 sales on Form 4. The insider trading page charts every trade.
When is ADC Therapeutics SA's next earnings date?
Around November 10, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — ADC Therapeutics SA announces its own schedule.